Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT05540587
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Sung-Hwan Kim
- Registry
-
NCT05540587
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05540587. Randomized; no masking; primary purpose treatment. Start 2022-05-20 (actual); primary completion 2024-05-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
- Acronym
- ERTEMIS
- Condition
- Mitral Valve Stenosis
- Condition
- Atrial Fibrillation
- Condition
- Stroke
- Condition
- Systemic Embolism
- Intervention (Drug)
- Edoxaban
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Sung-Hwan Kim
- Collaborator
- Daiichi Sankyo Korea Co., Ltd.
Record details
- Record id
cardio:ct-nct05540587- Content hash
c5398ef40b2d9205ea0c07753b083fce4fc9ff4c5ecd93454899d34dbf2fdb67